KYVERNA THERAPEUTICS INC (KYTX) Stock Income Statement
NASDAQ:KYTX - Nasdaq - US5019761049 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.03M | 5.66M | |||
| Operating Expenses | 160.65M | 62.41M | 36.41M | 32.00M | |||
| Research and Development | 127.43M | 49.92M | 28.40M | 25.85M | |||
| Selling, General, and Administrative Expenses | 33.22M | 12.48M | 8.01M | 6.15M | |||
| Operating Income | -160.65M | -62.41M | -29.38M | -26.35M | |||
| Interest Income/Expense | 15.33M | 2.10M | 500.00K | -2.00K | |||
| Other Income/Expense | -91.00K | -55.00K | -9.00K | -2.00K | |||
| Income Before Taxes | -145.42M | -60.37M | -28.89M | -26.35M | |||
| Net Income | -145.42M | -60.37M | -28.89M | -26.35M | |||
| EBITDA | -158.50M | -60.70M | -28.33M | -25.76M | |||
| Per Share Data | |||||||
| EPS Diluted Total Ops | -3.37 | -1.40 | -0.71 | -0.65 | |||
| Non GAAP EPS | -3.38 | N/A | N/A | N/A | |||
| Statistics | |||||||
| Profit Margin | N/A | N/A | -411.29% | -465.88% | |||
| Operating Profit Margin | N/A | N/A | -418.28% | -465.81% | |||
All data in USD